Heparin Market Report 2025 | Global Analysis by Key Players, Application and Industry Overview

The global heparin market size was estimated at USD 6.49 billion in 2018and is projected to expand at a CAGR of 1.6%.

The global Heparin Market size is expected to reach USD 7.4 billion by 2026, according to a new report by Grand View Research, Inc. It is projected to register a CAGR of 1.6% during the forecast period. Rising prevalence cardiovascular disorders, deep vein thrombosis, and renal diseases among other chronic diseases is expected to boost the growth.

According to the data published in the American Heart Association, in 2018, approximately 92.1 million American adults were living with some form of cardiovascular diseases. Coronary heart disease is one of the leading cause of deaths in U.S. Furthermore, it was estimated that more than 23.6 million deaths will be observed by 2030 due to cardiovascular diseases.

Increasing demand for transfusion of blood, blood components, and plasma derivatives during surgical procedures, treatment of infectious diseases, and increasing survival rate are high impact rendering drivers for growth of the heparin market during the forecast period. Increasing demand for RBCs and platelets by various hospital divisions and clinics is expected to have a positive impact on the growth.

Growing geriatric population is anticipated to propel the market growth. According to an article published in 2018 in the United States Census Bureau, it is estimated that by 2035, population aged 65 years and above is expected to reach 78 million whereas children under the age of 18 may reach around 76.7million.

Rising incidence of immunological diseases, thrombosis, and hemostasis is likely to result in high demand for therapeutic plasma proteins. Manufacturing of plasma proteins led to an increase in the demand for purified plasma, further expected to fuel the market over the forecast period.

Browse Details of Report @ https://www.grandviewresearch.com/industry-analysis/heparin-market

Further key findings from the report suggest:

• Low molecular weight heparin led the type segment in 2018 owing to its more predictable anticoagulant effect
• In 2018, ultra-low molecular weight heparin was estimated to be the fastest growing segment, owing to commercialization of enhanced version of products with improved pharmacological effects
• Subcutaneous route of administration led the market in 2018 and is estimated to be the fastest growing segment over the forecast period due to ease of administration
• Coronary artery disease was considered to be the largest application segment in 2018 and venous thromboembolism is projected to be the fastest growing segment in near future
• In 2018, outpatient led the end use segment and was estimated to register the fastest growth in the forthcoming years
• North America held the largest market share in 2018 owing to increasing prevalence of cardiovascular disorders and sports injuries. Asia Pacific is estimated to be the fastest growing segment over the forecast period
• Some of the key companies operating in the heparin market are GlaxoSmithKline plc; Pfizer, Inc.; Baxter; Leo Pharma A/S; Sanofi; Dr. Reddy’s Laboratories Ltd.; Aspen Holdings; B. Braun Medical Inc.; Fresenius SE & Co. KGaA; and Teva Pharmaceutical Industries Ltd